Key Therapeutics, LLC

Cash burn of $717,000 for the quarter ended December 31, 2022, 68% less than prior quarter cash burn of $2,235,000 Revenues for three and nine months ended December 31, 2022 essentially flat with strong performance in international sales European revenues increased 51% for the quarter and 29% for the nine months ended December 31, 2022, compared to the same periods prior year BOULDER, CO / ACCESSWIRE / February 14, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its third fiscal quarter and nine months ended December 31, 2022. "Our revenues remain strong despite overall economic trends such as inflation, and reduced consumer spending. These trends affected our U.S. business resulting in a decline in the sales of our consumer products. However, our international sales increased in the nine months ended December 31, 2022 compared to the same period in the prior year, with the largest increases in Europe and Latin America. We continue to grow our distributor network, recently adding partners in the U.S. and in Asia, and expanding our product offerings in many regions. We expect our ongoing efforts to add distributors and introduce new products to result in meaningful impacts to future results," said Amy Trombly, CEO of Sonoma. She continued, "Our sharply reduced cash burn for the quarter, combined with $2.5 milllion raised since quarter end, places Sonoma in a solid position as we head toward the end of our fiscal year." Business Highlights Sonoma continued to expand its business by launching new products and building new partnerships while growing existing distributor relationships and seeking additional regulatory approvals: On January 4, 2023, Sonoma launched a line of office dispense products exclusively for skin care professionals. These products include Regenacyn ® Plus Scar Management Hydrogel, Reliefacyn ® Plus Itch-Burn-Rash-Pain Relief Hydrogel, and Rejuvacyn ® Plus Skin Repair Cooling Mist, all in prescription strength formulations. Sonoma is targeting its office distribution program to dermatology practices and medical spas, offering improved outcomes, convenience, and lower healthcare costs for clients while providing an additional source of income for skin care professionals. Sonoma's office dispense products can be purchased by skin care professionals directly on our website at . In January 2023, Sonoma's Microcyn ® Rx products, including wound care, prescription dermatology products, Celacyn ® and Levicyn ® , and prescription eye care Acuicyn ® , received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA), enabling our partner, EMC Pharma, LLC to enter into distribution agreements for these products with federal customers. On January 26, 2023, Sonoma entered into a new partnership with one of the largest pharmaceutical companies in South Korea, Daewoong Pharmaceuticals, for the exclusive distribution of Microcyn technology-based Primocyn TM Skin Solution. In January 2023, Sonoma continued to expand its U.S. distributor network by partnering with Key Therapeutics, LLC, which will be introducing Sonoma's new line of pediatric care products to pediatricians in the United States. Results for the Quarter Ended December 31, 2022 Revenues for the quarter ended December 31, 2022 of $2.9 million increased slightly compared to the same period last year. European sales increased by 51%, reflecting an increase in demand for our wound care products as well as the introduction of several new products in Europe. Latin America revenue also increased compared to the same period last year. Decreased revenues in the United States were primarily the result of a decline in sales of our consumer-focused animal health care products as well as an overall retail market slowdown. The decrease in Rest of World revenue was due to decreased disinfectant sales in the Middle East that was partially offset by increased sales in India. The decrease in Asia revenue for the three months ended December 31, 2022 was due to timing of sales with Asian customers receiving higher values of sales earlier in the year compared to the third quarter. Sonoma's revenues tend to be choppy when viewed on a quarterly basis due to international customers placing larger but less frequent orders to benefit from quantity discounts and reduced shipping costs. For the quarter ended December 31, 2022, Sonoma reported revenues of $2.9 million and cost of revenues of $2.1 million, resulting in gross profit of $0.8 million, or 28% of revenue, compared to a gross profit of $1.2 million, or 41% of revenue, for the same period last year. Gross margins decreased by 13% for the quarter ended December 31, 2022 when compared to the same period last year as a result of overall product mix, lower manufacturing levels and higher costs of materials and transportation. Total operating expenses during the third quarter of fiscal year 2023 were $2.7 million, up $0.5 million, or 23%, when compared to $2.2 million during the same period in the prior year, as a result of closing down our Woodstock, GA facility and moving finance and operations staff to our Boulder, CO headquarters, as well as $350,000 of additional expenses for settling a long term contract, each of which management expects to be a one-time event. We continue to tightly manage expenses across all of our operations. Net loss before income tax for the quarter was $1.9 million, compared to a net loss of $0.9 million for the same period last year. EBITDAS loss for the quarter ended December 31, 2022 of $1.6 million was higher by $0.7 million, compared to an EBITDAS loss of $0.9 million for the same period last year. Results for the Nine Months Ended December 31, 2022 Revenues of $10.3 million for the nine months ended December 31, 2022 were essentially flat compared to the same period last year. Revenues increased in Europe, Asia, and Latin America. Decreased sales in the United States were due to the conversion of our prescription dermatology business to a distribution model and a decline in sales of our consumer-focused animal health care products as well as an overall retail market slowdown. The decrease in Rest of World revenue was due to decreased disinfectant sales in the Middle East that was partially offset by increased sales in India. For the nine months ended December 31, 2022, Sonoma reported revenues of $10.3 million and cost of revenues of $6.6 million, resulting in gross profit of $3.6 million, or 35% of revenues, compared to a gross profit of $3.9 million or 38% or revenues in the same period last year. The decrease in gross profit margin for the nine months ended December 31, 2022 was primarily due to product mix and higher costs of materials and transportation. Total operating expenses during the nine months ended December 31, 2022 of $7.0 million increased by $0.3 million, or 4%, compared to $6.7 million during the same period last year due to $350,000 of additional expenses for settling a long term contract and some increased expenses related to closing the Woodstock, GA office, each of which management expects to be a one-time event. Net loss before taxes for the nine months ended December 31, 2022 was $3.7 million, compared to a net loss before taxes of $2.1 million for the same period in prior year. EBITDAS loss for the nine months ended December 31, 2022 of $2.8 million was higher by $0.3 million, compared to an EBITDAS loss of $2.5 million for the same period last year. About Sonoma Pharmaceuticals, Inc. Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care, and dermatological conditions. The company's products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma's stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at . For partnership opportunities, please contact businessdevelopment@sonomapharma.com . Forward-Looking Statements Except for historical information herein, matters set forth in this press release are forward looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "expect," "continue," "believe" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the Covid pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law. Sonoma Pharmaceuticals™, Microcyn ® , Regenacyn ® , Reliefacyn ® , Rejuvacyn ® , Celacyn ® , Levicyn ® and Acuicyn ® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners. Media and Investor Contact: Sonoma Pharmaceuticals, Inc. ir@sonomapharma.com SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share amounts) December 31, 2022 March 31, 2022 ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 2,634 $ 7,396 Accounts receivable, net 2,297 2,407 Inventories, net 2,849 2,663 Prepaid expenses and other current assets 3,230 3,746 Current portion of deferred consideration, net of discount 222 218 Total current assets 11,232 16,430 Property and equipment, net 314 320 Operating lease, right of use assets 471 559 Deferred tax asset 1,089 829 Deferred consideration, net of discount, less current portion 514 630 Other assets 308 77 Total assets $ 13,928 $ 18,845 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,302 $ 1,641 Accrued expenses and other current liabilities 2,201 1,843 Deferred revenue 100 1,223 Deferred revenue Invekra 55 54 Current portion of debt-PPP - 120 Short-term debt - 688 Operating lease liabilities 276 250 Total current liabilities 3,934 5,819 Long-term deferred revenue Invekra 128 182 Long-term debt 15 - Withholding tax payable 4,097 3,838 Operating lease liabilities, less current portion 195 309 Total liabilities 8,369 10,148 Commitments and Contingencies (Note 5) Stockholders' Equity: Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2022 and March 31, 2022, respectively, no shares issued and outstanding at December 31, 2022 and March 31, 2022, respectively - - Common stock, $0.0001 par value; 24,000,000 shares authorized at December 31, 2022 and March 31, 2022, respectively, 3,109,652 and 3,100,937 shares issued and outstanding at December 31, 2022 and March 31, 2022, respectively (Note 7) 2 2 Additional paid-in capital 197,939 197,370 Accumulated deficit (188,206 ) (184,363 ) Accumulated other comprehensive loss (4,176 ) (4,312 ) Total stockholders' equity 5,559 8,697 Total liabilities and stockholders' equity $ 13,928 $ 18,845 SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Comprehensive Income (Loss) (In thousands, except per share amounts) (Unaudited) Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 Revenues $ 2,944 $ 2,902 $ 10,258 $ 10,330 Cost of revenues 2,113 1,699 6,645 6,433 Gross profit 831 1,203 3,613 3,897 Operating expenses Research and development - 26 6 121 Selling, general and administrative 2,665 2,135 7,030 6,603 Total operating expenses 2,665 2,161 7,036 6,724 Loss from operations (1,834 ) (958 ) (3,423 ) (2,827 ) Interest income (expense), net 1 3 4 (1 ) Other income (expense), net (73 ) 11 (327 ) 542 Gain on sale of assets 1 - 1 150 Loss before income taxes (1,905 ) (944 ) (3,745 ) (2,136 ) Income tax benefit (expense) (34 ) - (98 ) (6 ) Net loss $ (1,939 ) $ (944 ) $ (3,843 ) $ (2,142 ) Net loss per share: basic $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) Net loss per share: diluted $ (0.62 ) $ (0.31 ) $ (1.24 ) $ (0.85 ) Weighted-average number of shares: basic 3,107 3,080 3,104 2,507 Weighted-average number of shares: diluted 3,107 3,080 3,104 2,507 Other comprehensive loss Net loss $ (1,939 ) $ (944 ) $ (3,843 ) $ (2,142 ) Foreign currency translation adjustments 235 (65 ) 136 8 Comprehensive loss $ (1,704 ) $ (1,009 ) $ (3,707 ) $ (2,134 ) SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (In thousands) (Unaudited) Three Months Ended December 31, Nine Months Ended December 31, 2022 2021 2022 2021 (1) Loss from operations minus non-cash expenses EBITDAS loss: GAAP operating loss as reported $ (1,834 ) $ (958 ) $ (3,423 ) $ (2,827 ) Non-cash adjustments: Stock-based compensation 242 55 569 169 Depreciation and amortization 31 51 91 151 Non-GAAP income (loss) from operations minus non-cash expenses EBITDAS income (loss) $ (1,561 ) $ (852 ) $ (2,763 ) $ (2,507 ) (2) Net loss minus non-cash and one-time expenses: GAAP net income (loss) as reported $ (1,939 ) $ (944 ) $ (3,843 ) $ (2,142 ) Non-cash adjustments: Stock-based compensation 242 55 569 169 Non-cash foreign exchange transaction losses 73 - 327 Income taxes 34 - 98 - Depreciation and amortization 31 51 91 151 Non-GAAP net income (loss) minus non-cash expenses $ (1,559 ) $ (838 ) $ (2,758 ) $ (1,822 ) (3) Operating expenses minus non-cash expenses GAAP operating expenses as reported $ 2,665 $ 2,161 $ 7,030 $ 6,724 Non-cash adjustments: Stock-based compensation (242 ) (55 ) (569 ) (169 ) Depreciation and amortization (31 ) (51 ) (91 ) (151 ) Non-GAAP operating expenses minus non-cash expenses $ 2,392 $ 2,055 $ 6,370 $ 6,404 Income (loss) from continuing operations minus non-cash expenses (EBITDAS) is a non-GAAP financial measure. The company defines operating income (loss) minus non-cash expenses as GAAP reported operating income (loss) minus operating depreciation and amortization, and operating stock-based compensation. The company uses this measure for the purpose of modifying the operating loss to reflect direct cash related transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. Net income (loss) minus non-cash and one time expenses is a non-GAAP financial measure. The company defines net income (loss) minus non-cash expenses as GAAP reported net income (loss) minus depreciation and amortization, stock-based compensation, forgiveness of PPP loan and non-cash foreign exchange transaction losses. The company uses this measure for the purpose of modifying the net loss to reflect only those expenses to reflect direct cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. Operating expenses minus non-cash expenses is a non-GAAP financial measure. The company defines operating expenses minus non-cash expenses as GAAP reported operating expenses minus operating depreciation and amortization, and operating stock-based compensation. The company uses this measure for the purpose of identifying total operating expenses involving cash transactions during the measurement period. Non-GAAP measures should not be considered a substitute for financial measures presented in accordance with GAAP. Non-GAAP measures are not always consistent across, or comparable with, non-GAAP measures disclosed by other companies. SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES PRODUCT RELATED REVENUE SCHEDULES (In thousands) (Unaudited) The following table presents the company's disaggregated product revenues by geographic region: Three Months Ended December 31, (In thousands) 2022 2021 $ Change % Change United States $ 761 $ 933 $ (172 ) (18 %) Europe 1,104 731 373 51 % Asia 514 664 (150 ) (23 %) Latin America 384 273 111 41 % Rest of the World 181 301 (120 ) (40 %) Total $ 2,944 $ 2,902 $ 42 1 % Nine Months Ended December 31, (In thousands) 2022 2021 $ Change % Change United States $ 2,603 $ 3,872 $ (1,269 ) (33 %) Europe 3,117 2,419 698 29 % Asia 1,952 1,810 142 8 % Latin America 1,827 1,356 471 35 % Rest of the World 759 873 (114 ) (13 %) Total $ 10,258 $ 10,330 $ (72 ) (1 %) SOURCE: Sonoma Pharmaceuticals, Inc. View source version on accesswire.com:

Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering. Over time, several gene therapies have been developed for the treatment of both simple and complex genetic disorders. In fact, there are 10 approved gene therapies (recent examples include Zolgensma, ZyntegloT and Collategene) to date, and more than a thousand product candidates being evaluated in clinical trials, worldwide. Considering the current pace of research and product development activity in this field, experts believe that the number of clinical research initiatives involving gene therapies are likely to grow by 17% annually. In this context, the USFDA released a notification, mentioning that it now expects to receive twice as many gene therapy applications each year, starting 2020. Despite the ongoing pandemic, it is worth highlighting that gene therapy companies raised approximately USD 5.5 billion in capital investments, in 2020 alone. This is indicative of the promising therapeutic potential of this emerging class of pharmacological interventions, which has led investors to bet heavily on the success of different gene therapy candidates in the long term. Several technology platforms are currently available for discovery and development of various types of gene therapies. In fact, advances in bioanalytical methods and genome editing and manipulation technologies, have enabled the development of novel therapy development tools/platforms. In fact, technology licensing is a lucrative source of income for stakeholders in this industry, particularly for those with proprietary gene editing platforms. Given the growing demand for interventions that focus on the amelioration of the underlying (genetic) causes of diseases, it is expected that the gene therapy pipeline will continue to steadily expand. Moreover, promising results from ongoing clinical research initiatives are likely to bring in more investments to support therapy product development initiatives in this domain. Therefore, we are led to believe that the global gene therapy market is poised to witness significant growth in the foreseen future. The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, immunotherapies and gene editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. Key Questions Answered Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. GENE DELIVERY VECTORS 5. REGULATORY LANDSCAPE AND REIMBURSEMENT SCENARIO 6. MARKET OVERVIEW 7. COMPETITIVE LANDSCAPE 8. MARKETED GENE THERAPIES 9. KEY COMMERCIALIZATION STRATEGIES 10. LATE STAGE GENE THERAPIES 11. EMERGING TECHNOLOGIES 12. KEY THERAPEUTICS AREAS 13. PATENT ANALYSIS 14. MERGERS AND ACQUISITIONS 15. FUNDING AND INVESTMENT ANALYSIS 16. CLINICAL TRIAL ANALYSIS 17. COST PRICE ANALYSIS 18. BIG PHARMA PLAYERS: ANALYSIS OF GENE THERAPY RELATED INITIATIVES 19. DEMAND ANALYSIS 20. MARKET FORECAST AND OPPORTUNITY ANALYSIS 21. VECTOR MANUFACTURING 22. CASE STUDY: GENE THERAPY SUPPLY CHAIN 23. CONCLUSION A Selection of Companies Mentioned Include: For more information about this report visit About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030" report has been added to ResearchAndMarkets.com's offering. Over time, several gene therapies have been developed for the treatment of both simple and complex genetic disorders. In fact, there are 10 approved gene therapies (recent examples include Zolgensma, ZyntegloT and Collategene) to date, and more than a thousand product candidates being evaluated in clinical trials, worldwide. Considering the current pace of research and product development activity in this field, experts believe that the number of clinical research initiatives involving gene therapies are likely to grow by 17% annually. In this context, the USFDA released a notification, mentioning that it now expects to receive twice as many gene therapy applications each year, starting 2020. Despite the ongoing pandemic, it is worth highlighting that gene therapy companies raised approximately USD 5.5 billion in capital investments, in 2020 alone. This is indicative of the promising therapeutic potential of this emerging class of pharmacological interventions, which has led investors to bet heavily on the success of different gene therapy candidates in the long term. Several technology platforms are currently available for discovery and development of various types of gene therapies. In fact, advances in bioanalytical methods and genome editing and manipulation technologies, have enabled the development of novel therapy development tools/platforms. In fact, technology licensing is a lucrative source of income for stakeholders in this industry, particularly for those with proprietary gene editing platforms. Given the growing demand for interventions that focus on the amelioration of the underlying (genetic) causes of diseases, it is expected that the gene therapy pipeline will continue to steadily expand. Moreover, promising results from ongoing clinical research initiatives are likely to bring in more investments to support therapy product development initiatives in this domain. Therefore, we are led to believe that the global gene therapy market is poised to witness significant growth in the foreseen future. The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies, oncolytic viral therapies, immunotherapies and gene editing therapies. The study also features an elaborate discussion on the future potential of this evolving market. Key Questions Answered Who are the leading industry players engaged in the development of gene therapies? How many gene therapy candidates are present in the current development pipeline? Which key disease indications are targeted by such products? Which types of vectors are most commonly used for effective delivery of gene therapies? What are the key regulatory requirements for gene therapy approval, across various geographies? Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of development? What are the different pricing models and reimbursement strategies currently being adopted for gene therapies? What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies? Who are the key CMOs/CDMOs engaged in supplying viral/plasmid vectors for gene therapy development? What are the key value drivers of the merger and acquisition activity in the gene therapy industry? Who are the key stakeholders that have actively made investments in the gene therapy domain? Which are the most active trial sites related to this domain? How is the current and future market opportunity likely to be distributed across key market segments? Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. GENE DELIVERY VECTORS 5. REGULATORY LANDSCAPE AND REIMBURSEMENT SCENARIO 6. MARKET OVERVIEW 7. COMPETITIVE LANDSCAPE 8. MARKETED GENE THERAPIES 9. KEY COMMERCIALIZATION STRATEGIES 10. LATE STAGE GENE THERAPIES 11. EMERGING TECHNOLOGIES 12. KEY THERAPEUTICS AREAS 13. PATENT ANALYSIS 14. MERGERS AND ACQUISITIONS 15. FUNDING AND INVESTMENT ANALYSIS 16. CLINICAL TRIAL ANALYSIS 17. COST PRICE ANALYSIS 18. BIG PHARMA PLAYERS: ANALYSIS OF GENE THERAPY RELATED INITIATIVES 19. DEMAND ANALYSIS 20. MARKET FORECAST AND OPPORTUNITY ANALYSIS 21. VECTOR MANUFACTURING 22. CASE STUDY: GENE THERAPY SUPPLY CHAIN 23. CONCLUSION A Selection of Companies Mentioned Include: 4BIO Capital 4D Molecular Therapeutics AavantiBio aaVective AAVogen AbbVie Allergan AlphaVax Altheia Science Amgen Amplo Angionetics ApolloBio Arthrogen Astellas Pharma AstraZeneca Atlas Venture Atsena Therapeutics AVROBIO Baillie Gifford Baldota Group Bayer Biogen BridgeBio Bristol-Myers Squibb Calimmune Cardiogen Sciences Casdin Capital Codexis CSL Behring Editas Medicine Fundacion Sanfilippo B Google Ventures Gradalis Green Cross Holdings GSK Handl Therapeutics Hovione Scientia Intrexon Invus IVERIC bio Janssen Pharmaceuticals Johnson & Johnson Development Juda Capital K2 Venture Capital Lacerta Therapeutics MeiraGTx Merck MERITZ Securities Mitsubishi Tanabe Pharma MultiVir Myonexus Therapeutics Navega Therapeutics NeoMed Nerveda Omega Funds Omnes Capital OrbiMed ORI Capital Otonomy Oxford BioMedica Oxular REGENXBIO Renova Therapeutics Roche Sanofi StrideBio Surveyor Capital Syncona Synpromics T. Rowe Price Takeda Pharmaceutical Targovax Temasek Tenaya Therapeutics TheraBiologics Theravectys Tocagen WuXi AppTec XyloCor Therapeutics Ysios Capital Ziopharm Oncology For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900